TNF and inflammatory bowel disease: Three months after the second vaccination, significantly lower sVNT inhibition levels were detected in IBD patients receiving anti-TNF therapy compared to healthy controls (adalimumab: 69% (27–90%) vs. 96% (95–97%), p = 0.023; infliximab: 73% (42–84%) vs. 96% (95–97%), p = 0.001; Figure 2c,d).